INTRODUCTION
Liver cancer is the sixth most commonly diagnosed cancer worldwide (4.7% of all cases), and its fatality rate (8.3%) is the third highest among malignant tumors in men and women combined. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, comprising 75–85% of all liver cancer cases [1]. Therefore, there is a great need for a better understanding of the mechanisms underlying HCC pathogenesis.

Sorafenib, an oral multi-kinase inhibitor, exerts anti-angiogenic and anti-proliferative effects by repressing serine/threonine kinases and receptor tyrosine kinases [2]. Currently, sorafenib is the first-line standard treatment for advanced HCC, and it demonstrates an obvious curative effect. Sorafenib can extend the median overall survival of patients with advanced-stage HCC from 8 to 11 months [3]. However, the benefits of sorafenib are limited. Only ~30% of patients benefit from the drug, but they too acquire resistance within 6 months, suggesting the existence of primary and acquired sorafenib resistance in HCC [4]. Therefore, research on molecular regulation in sorafenib-resistant HCC cells is urgently warranted.

Sorafenib can induce endoplasmic reticulum (ER) stress-related apoptosis in HCC. Subsequently, the unfolded protein response (UPR) — a well-defined process that plays a vital role in restoring homeostasis after the accumulation of potentially toxic misfolded proteins — is required to restore ER homeostasis [5, 6]. In response to chronic stress, some cancer cells constitutively activate the UPR pathway and become resistant to cell death [7]. IRE1α, a UPR sensor, can protect cells against ER stress [5]. Studies have demonstrated that the IRE1α–XBP1s pathway is important for tumor survival under sorafenib-induced ER stress [8]. Sustained activation of IRE1α–XBP1s signaling not only confers sorafenib resistance to HCC cells but also contributes to tumorigenesis and the epithelial–mesenchymal transition (EMT) [9, 10]. Hence, it is necessary to investigate the role of the UPR, and especially that of the IRE1α–XBP1s pathway, in sorafenib resistance in HCC. A previous study found that the IRE1α–XBP1s pathway can directly activate c-MYC signaling [11]. Moreover, MYC dysregulation is commonly observed in multiple human cancers, including HCC [12]. Further, c-MYC signaling plays an important role in drug resistance [13]. Unfortunately, owing to its "undruggable" protein structure, there is no specific therapy that directly destroys MYC function. Therefore, identifying the key genes upstream of MYC can help in developing alternative strategies for the treatment of HCC, and especially sorafenib-resistant HCC.
Reticulocalbin 1 (RCN1) is a member of the CREC family. This protein, which is located in the ER, consists of an ER-retention motif, HDEL, and six EF-hand motifs in its carboxyl-terminal sequence. This Ca$^{2+}$ binding protein is involved in the regulation of Ca$^{2+}$-dependent activity in the ER lumen and is present throughout the secretory pathway in mammalian cells [14]. RCN1 overexpression has been identified in various tumors, including liver, lung, breast, colorectal, prostate, and nasopharyngeal cancers [14–20]. In particular, RCN1 was implicated in the regulation of drug resistance, and RCN1 knockdown was found
to reduce the resistance of nasopharyngeal carcinoma (NPC) cells/tissues to doxorubicin, promoting NPC cell death [21]. RCN1 was also found to be upregulated in doxorubicin-resistant uterine cancer [22]. However, the exact mechanisms of RCN1-mediated sorafenib resistance and tumorigenesis in HCC are unclear.

Therefore, in the present study, we aimed to examine whether RCN1 participates in sorafenib resistance and hepatocarcinogenesis in HCC and to clarify the molecular mechanism of its role in this type of cancer.

RESULTS

**RCN1 is upregulated in sorafenib-resistant HCC cells and may predict poor patient prognosis**

We calculated the half maximal inhibitory concentration (IC50) of sorafenib in the resistant cell lines using the MTT test (Fig. S1A). Using the annexin V-propidium iodide (PI) assay, we found that sorafenib-resistant cells had a greater ability to resist sorafenib-induced apoptosis (Fig. 1A). Moreover, sorafenib-resistant cells had a greater capability of initiating tumor formation in vivo (Fig. 1B). More importantly, the diameter and numbers of tumors were larger in the sorafenib resistance group (Fig. 1C). These data demonstrated the successful establishment of sorafenib-resistant cell lines.

The GSE94550 dataset, which contains information on sorafenib resistance in HCC, was analyzed using the R language. We found 1145 genes differentially expressed between cells that were sensitive to sorafenib and those that had acquired resistance to the drug (Fig. 1D). Gene ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and gene set enrichment analysis (GSEA) were performed to further examine the functional alterations associated with sorafenib resistance (Fig. S1B–E). Subsequently, we created a heatmap of the 20 genes showing the highest fold change (logFC > 3), as illustrated in Fig. 1E. Using qRT-PCR, we confirmed that **RCN1**, one of the genes with the highest fold change, was significantly upregulated in sorafenib-resistant Huh7 and HepG2 cells (Fig. 1F). We also verified that **RCN1** protein levels were indeed elevated in sorafenib-resistant cells (Fig. 1G). Then, we evaluated **RCN1** expression in sorafenib-resistant (n = 15) and sorafenib-sensitive (n = 27) HCC samples from patients (Fig. 1H). The clinical characteristics of sorafenib-resistant patients are summarized in Table 1. To further elucidate the role of **RCN1** in HCC, we examined **RCN1** expression in HCC tumor tissues and matched tumor-adjacent tissues (n = 68) (Fig. 1I). We observed that high levels of **RCN1** were significantly associated with a larger tumor size, microvascular invasion and higher TNM stage (Table 2). Using the GEPIA website, we found that **RCN1** expression was significantly higher in tumor tissues than in the adjacent tissues (Fig. 1J). We analyzed the effect of **RCN1** expression on the prognosis of HCC patients and found that patients with a high expression of **RCN1** had a worse prognosis (Fig. 1K).

Taken together, these data suggested that **RCN1** could be a potential prognostic marker in HCC patients, and further basic research on this topic was warranted.

**RCN1 promotes sorafenib resistance and HCC malignancy**

Among the five sorafenib-sensitive HCC cell lines — i.e., Huh7, HepG2, MHCC-LM3, MHCC-97H, and Hep3B — the expression of **RCN1** was the lowest in Huh7 cells and the highest in Hep3B cells (Fig. S2A). Further, **RCN1** overexpression in Huh7 cells resulted in an enhanced ability to resist sorafenib-induced apoptosis, whereas the knockdown of **RCN1** in Hep3B cells led to a decline in resistance (Fig. S2B, C). These findings confirmed the link between **RCN1** expression and sorafenib resistance. In order to explore the role of **RCN1** in sorafenib resistance, we knocked down **RCN1** in sorafenib-resistant Huh7 cells (Fig. 2A). **RCN1** silencing reduced the ability of sorafenib-resistant cells to resist sorafenib-induced apoptosis (Fig. 2B). Moreover, when we subcutaneously injected sorafenib-resistant Huh7 cells into sorafenib-treated nude mice, **RCN1** knockdown significantly enhanced the effectiveness of sorafenib against HCC (Fig. 2C). Subsequently, when a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay was performed, a higher percentage of apoptotic cells was observed in resected **RCN1**-knockdown xenografts (Fig. 2D). In addition, the expression of apoptosis-related proteins also significantly changed after **RCN1** knockdown, further demonstrating that **RCN1** promoted apoptosis resistance (Fig. 2E).

Data from the TIMER2.0 website showed a positive correlation between the expressions of **RCN1** and proliferating cell nuclear antigen (PCNA) (Fig. S2D). The CCK-8 assay further revealed that **RCN1** knockdown reduced proliferation in sorafenib-resistant cells (Fig. S2E). Consistent with this, EdU incorporation assays also showed that **RCN1** knockdown resulted in a significant inhibition of the proliferation of sorafenib-resistant cells (Fig. 2F). Examination of clinical tumor tissues using IHC also proved that the expression of **RCN1** was positively correlated with that of PCNA (n = 68) (Fig. 2G).

Further, transwell assays showed that **RCN1** knockdown reduced the migratory and invasive capacities of sorafenib-resistant cells (Fig. 2H). We hypothesized that **RCN1** played a role in EMT, and we further investigated the correlation between the expression of EMT markers and that of **RCN1** using the TIMER2.0 website (Fig. S2F). We found that high **RCN1** expression inhibited E-cadherin levels and augmented vimentin and N-cadherin levels in sorafenib-resistant cells (Fig. 2I).

**RCN1 contributes to selective activation of the unfolded protein response**

We speculated that the role of **RCN1** in sorafenib-resistant cells may be related to ER stress. Transmission electron microscopy revealed that sorafenib-resistant cells had an irregular ER structure, with substantially expanded membranes and distended lumens when compared with sorafenib-resistant sh**RCN1** cells (Fig. 3).
Previous studies have shown that RCN1 can resist tunicamycin (TM)-induced apoptosis in HepG2 cells by inhibiting the PERK-CHOP signaling pathway [23]. Similar results were observed after RCN1 knockdown in sorafenib-sensitive Huh7 cells after TM treatment (Fig. S3B).

Subsequently, we explored the expression of IRE1, CHOP, GRP78, and XBP1s in sorafenib-resistant and -sensitive cells and found XBP1s to be significantly upregulated in sorafenib-resistant cells (Fig. 3A and S3C). In addition, knocking down RCN1 in sorafenib-resistant Huh7 and HepG2 cells significantly reduced the expression of p-IRE1α and XBP1s (Fig. 3B), although it had no effect on the expression of p-PERK, CHOP, and GRP78 (Fig. S3D).

Moreover, the expression of p-IRE1α and XBP1s was also increased in RCN1-overexpressing sorafenib-sensitive Huh7 cells (Fig. S3E). The results suggested that in sorafenib-resistant cells, RCN1 may activate the UPR via the IRE1α–XBP1s pathway instead of inhibiting ER stress through the PERK-CHOP pathway. Notably, the total protein content of XBP1 was also significantly reduced in RCN1-knockdown drug-resistant cells (Fig. 3C).

Finally, we investigated whether IRE1α is necessary for RCN1-mediated XBP1 splicing. IRE1α silencing in sorafenib-resistant cells markedly reduced XBP1 splicing, suggesting that IRE1α is required for RCN1-mediated XBP1 splicing (Fig. 3D). To confirm this, we examined the effect of IRE1α overexpression on XBP1 splicing in RCN1-deficient cells. IRE1α overexpression upregulated XBP1 splicing in sorafenib-resistant RCN1-knockdown cells (Fig. 3E).

Taken together, our results indicated that in sorafenib-resistant cells, RCN1 has a specific role in the regulation of the IRE1α–XBP1 pathway as part of the UPR.

IRE1α–XBP1s signaling is crucial for sorafenib resistance and HCC malignancy

Depending on the duration and degree of ER stress, UPR can either provide survival signals by activating adaptive and anti-apoptotic pathways or activate signaling programs that induce cell death [24]. Therefore, we speculated that the anti-apoptotic effect of RCN1 on sorafenib-resistant cells might depend on the IRE1α–XBP1 signaling pathway. Interestingly, after knocking down IRE1α, the resistance to sorafenib could be reversed (Fig. 4A). Additionally, we used MKC8866, an optimized IRE1α RNase-specific inhibitor that can suppress XBP1s expression, to study the effect of XBP1s in sorafenib-resistant cells. MKC8866 treatment could also reverse the resistance of sorafenib-resistant cells. MKC8866 treatment could also reverse the resistance of sorafenib-resistant cells. MKC8866 treatment could also reverse the resistance of sorafenib-resistant cells. MKC8866 treatment could also reverse the resistance of sorafenib-resistant cells.

| Characteristics       | Total | Sorafenib-sensitive | Sorafenib-resistant | χ² | p-value |
|-----------------------|-------|---------------------|---------------------|----|---------|
| RCN1 expression       | 8.849 |                     |                     |    | 0.003*  |
| Low                   | 24    | 20 (74.1)           | 4 (26.8)            |    |         |
| High                  | 18    | 7 (25.9)            | 11 (73.2)           |    |         |
| Age (y)               | 0.616 |                     |                     |    | 0.433   |
| <50                   | 11    | 6 (22.2)            | 5 (33.3)            |    |         |
| ≥50                   | 31    | 21 (71.9)           | 10 (66.7)           |    |         |
| Gender                | 2.696 |                     |                     |    | 0.101   |
| Male                  | 29    | 21 (71.9)           | 8 (53.3)            |    |         |
| Female                | 13    | 6 (25.9)            | 7 (46.7)            |    |         |
| Cirrhosis             | 0.305 |                     |                     |    | 0.580   |
| Present               | 22    | 15 (55.6)           | 7 (53.6)            |    |         |
| Absent                | 20    | 12 (44.4)           | 8 (53.4)            |    |         |
| HBV infection         | 0.017 |                     |                     |    | 0.895   |
| Positive              | 36    | 23 (85.2)           | 13 (86.7)           |    |         |
| Negative              | 6     | 4 (14.8)            | 2 (13.3)            |    |         |
| Tumor size (cm)       | 10.996|                     |                     |    | 0.001*  |
| <5                    | 20    | 18 (66.7)           | 2 (13.3)            |    |         |
| ≥5                    | 22    | 9 (33.3)            | 13 (86.7)           |    |         |
| Vascular invasion     | 7.135 |                     |                     |    | 0.008*  |
| Presence              | 25    | 12 (44.4)           | 13 (86.7)           |    |         |
| Absence               | 17    | 15 (55.6)           | 2 (13.3)            |    |         |
| AFP (ng/ml)           | 0.494 |                     |                     |    | 0.482   |
| ≤20                   | 23    | 15 (55.6)           | 8 (53.4)            |    |         |
| >20                   | 19    | 12 (44.4)           | 7 (46.6)            |    |         |
| TNM stage             | 6.067 |                     |                     |    | 0.014*  |
| I                     | 16    | 14 (51.9)           | 2 (13.3)            |    |         |
| II + III              | 26    | 13 (48.1)           | 13 (86.7)           |    |         |

*p-value < 0.05.
The RCN1 EFh1/2 domain binds to GRP78 and promotes the dissociation of GRP78 from IRE1α

According to the GEPIA database, the mRNA expression of RCN1 was not correlated with that of GRP78, IER1, and XBP1 in HCC (Fig. S4A). We aimed to ascertain whether RCN1 could influence the IRE1α-XBP1 pathway in other ways. After dissociation from GRP78, IRE1α undergoes dimerization and autophosphorylation, triggering conformational changes that activate its endoribonuclease domain, causing a reading frameshift and the translation of the active transcription factor XBP1 [25]. We examined whether the presence of RCN1 promotes the dissociation of GRP78 from IRE1α in sorafenib-resistant cells. Surprisingly, RCN1 silencing greatly increased the binding of GRP78 to IRE1α (Fig. 5A), consistent with the decrease in p-IRE1α levels observed after RCN1 knockdown (Fig. 3C). Using co-immunoprecipitation (co-IP) to examine cell lysates, we found that RCN1 and GRP78 interact physically in sorafenib-resistant Huh7 cells (Fig. 5B). To further identify the motif via which RCN1 interacts with GRP78, different HA-tagged RCN1 mutants were transfected into sorafenib-resistant cells. (Fig.5C). Co-IP revealed that the EFh1/2 domain of RCN1 was required for interaction with GRP78 in sorafenib-resistant cells (Fig. 5D).

RCN1 activates c-MYC signaling via the IRE1α–XBP1s pathway in sorafenib-resistant cells

In order to further identify the signaling pathways regulated by RCN1, we conducted GSEA by analyzing The Cancer Genome Atlas data. We observed that the activity of the c-MYC signaling pathway was positively correlated with the expression of RCN1 in 376 HCC tissues (Fig. 6A). In addition, according to the TIMER and GEPIA databases, the expression of RCN1 was correlated with the expression of MYC in HCC (Fig. S4B, C). Moreover, c-MYC levels were significantly higher in sorafenib-resistant cells than in sorafenib-sensitive cells (Fig. S4D). We observed reduced mRNA levels of MYC in RCN1-knockdown sorafenib-resistant cells (Fig. 6B), and accordingly, c-MYC protein levels were also found to be lower (Fig. 6C). Interestingly, c-MYC was also upregulated in RCN1-overexpressing sorafenib-sensitive Huh7 cells (Fig. S4E). Further, the intensity of c-MYC immunohistochemical staining in xenograft tumor sections from shRCN1 mice was significantly weaker than that in sections from shNC mice (Fig. 6D). Next, we stably knocked down MYC (Fig. 6E) in sorafenib-resistant cells Huh7 cells; we found an increase in cell apoptosis (Fig. 6F) along with a reduction in cell proliferation (Fig. 6G), invasion, and migration (Fig. 6H). MYC overexpression after RCN1 knockdown (Fig. 7A) decreased the sensitivity of drug-resistant Huh7 cells to sorafenib (Fig. 7B). Importantly, MYC overexpression rescued the inhibitory effect of RCN1 shRNA on proliferation, migration, and invasion in sorafenib-resistant cells (Fig. 7C, D).

Previous studies have shown that the IRE1α–XBP1s pathway can promote the development of prostate cancer by activating c-MYC signaling [11]. Therefore, we speculated that the

| Characteristics | Total | Low-RCN1 | High-RCN1 | χ²   | p-value |
|-----------------|-------|----------|-----------|------|---------|
| Age (y)         |       |          |           | 2.138| 0.144   |
| <50             | 15    | 5 (14.7) | 10 (29.4) | –    | –       |
| ≥50             | 53    | 29 (85.3)| 24 (70.6) | –    | –       |
| Gender          |       |          |           | 1.722| 0.189   |
| Male            | 47    | 26 (76.5)| 21 (61.8) | –    | –       |
| Female          | 21    | 8 (23.5) | 13 (38.2) | –    | –       |
| Cirrhosis       |       |          |           | 0.236| 0.627   |
| Present         | 32    | 15 (44.1)| 17 (50.0) | –    | –       |
| Absent          | 36    | 19 (55.9)| 17 (50.0) | –    | –       |
| HBV infection   |       |          |           | 0.108| 0.742   |
| Positive        | 57    | 29 (85.3)| 28 (82.4) | –    | –       |
| Negative        | 11    | 5 (14.7) | 6 (17.6)  | –    | –       |
| Tumor size (cm) |       |          |           | 11.691| 0.001* |
| <5              | 38    | 26 (76.5)| 12 (35.3) | –    | –       |
| ≥5              | 30    | 8 (23.5) | 22 (64.7) | –    | –       |
| Vascular invasion|      |          |           | 8.500| 0.004*  |
| Presence        | 35    | 11 (32.4)| 24 (70.6) | –    | –       |
| Absence         | 33    | 23 (67.6)| 10 (29.4) | –    | –       |
| AFP (ng/ml)     |       |          |           | 0.541| 0.462   |
| ≤20             | 29    | 13 (38.2)| 16 (47.1) | –    | –       |
| >20             | 39    | 21 (61.8)| 18 (52.9) | –    | –       |
| TNM stage       |       |          |           | 13.339| 0.000*  |
| I               | 31    | 23 (67.6)| 8 (23.5)  | –    | –       |
| II + III        | 37    | 11 (32.4)| 26 (76.5) | –    | –       |

*p-value < 0.05.

Table 2. Association between RCN1 expression and clinicopathological features in patients with HCC (n = 68).
increased XBP1 splicing caused by RCN1 overexpression in sorafenib-resistant cells might further affect the activation of the c-MYC signaling pathway. We analyzed the mRNA levels of MYC in IRE1-knockdown sorafenib-resistant cells and cells treated with MKC8866 and found that, as expected, the mRNA levels of MYC were both decreased in both (Fig. S4F). We found that the ectopic expression of flag–XBP1s in sorafenib-resistant cells activated the luciferase reporter driven by the c-MYC promoter in a dose-dependent manner (Fig. 7E). Therefore, our results showed that c-MYC signaling contributed to sorafenib...
resistance and HCC malignancy via the RCN1–IRE1α–XBP1s pathway (Fig. 7F).

A variety of cytokines and drugs lead to increased RCN1 expression

The tumor microenvironment refers to the environment surrounding a tumor. Cancer-associated fibroblasts (CAFs) are important tumor stromal cells [26]. We collected conditioned medium from patient-derived CAFs and co-cultured Huh7 or HepG2 cells in this medium in vitro. qRT-PCR showed that RCN1 was upregulated in HepG2 and HepG2 cells (Fig. 8A). However, the specific cytokines secreted by CAFs that contributed to the increase in RCN1 levels needed to be identified. It has been reported that the TNF-α-NFκB pathway is necessary for the increased expression of RCN1 [23]. Interestingly, TNF-α is mainly released from macrophages, and TNF-α can directly lead to tumor promotion or the apoptosis of tumor cells [27, 28]. Therefore, we added recombinant human TNF-α into the condition medium of Huh7 and HepG2 at a gradient concentration and found that RCN1 was upregulated in these cells in a concentration-dependent manner (Fig. 8B).

Lenvatinib is an oral small-molecule inhibitor of multi-receptor tyrosine kinases that has been approved for the first-line treatment of unresectable HCC. Lenvatinib dually inhibits the VEGF and FGF pathways and blocks proliferation signals from VEGFR and FGFFR, which are upregulated in HCC. Interestingly, we found that RCN1 knockdown caused a decrease in VEGFR (Fig. S4G). Additionally, RCN1 expression increased with increased doses of lenvatinib (Fig. 8C).

Regorafenib, a second-line treatment for patients with advanced HCC, has also provided some survival benefit in those showing progression on sorafenib treatment [29]. We found that RCN1 was upregulated after treatment with regorafenib in a dose-dependent manner (Fig. 8D). These results showed that the tumor microenvironment and a variety of drugs could promote RCN1 expression in liver cells (Fig. 8E).

DISCUSSION

HCC, one of the most common malignant tumors in the world [30], often results in a poor prognosis. Sorafenib is used as the first-line therapy for patients with advanced liver cancer. However, sorafenib responsiveness varies among patients with advanced HCC and most of them eventually develop drug resistance, necessitating the elucidation of the molecular mechanisms underlying sorafenib resistance.

In the present study, we found that RCN1 expression was upregulated in sorafenib-resistant HCC cells and that the presence of RCN1 conferred sorafenib resistance to these cells. Clinically, high RCN1 levels in human HCC were predictive of a worse prognosis, suggesting that RCN1 could serve as a biomarker in individualized HCC therapy. Mechanistic studies revealed that RCN1 blunts the efficacy of sorafenib and induces malignancy in HCC by activating the IRE1α–XBP1s–c-MYC pathway. Therefore, RCN1 may be an alternative target for HCC treatment.

GO enrichment analysis of the GSE94550 dataset (Fig. S1B) revealed enrichment for widely distributed and extensive GO terms under the “biological processes” domain. High enrichment was observed for “signal transduction,” “positive regulation of cell proliferation,” “response to hypoxia,” and “steroid metabolic process,” suggesting that the biological processes of sorafenib-resistant cells are highly different. Due to the limitations of differentially expressed gene (DEG) enrichment analysis, some important genes with minor changes may have been excluded. Thus, we conducted GSEA to further explore the functional changes related to sorafenib resistance (Fig. S1D). As expected, GSEA of the HALLMARK gene set revealed a dramatic impairment in EMT. Accordingly, in our study, we found that RCN1 is closely related to EMT. The TNF-α-NFκB pathway, which plays a pivotal role in regulating cell proliferation, was significantly upregulated in sorafenib-resistant cells. Interestingly, it has been reported that RCN1 can be upregulated via the TNF-α-NFκB pathway [23]. Moreover, the HPOXIA gene set was also upregulated in sorafenib-resistant cells, consistent with the DEG enrichment results. Compared with normal liver tissue, liver cancer tissue has abnormally low perfusion, which leads to severe hypoxia. In addition, the anti-vascular effects of sorafenib aggravate hypoxia. Three main O2-sensing pathways promote hypoxia tolerance [31]. First, hypoxia stabilizes hypoxia-inducible factor (HIF) 1α, which facilitates the transcriptional activation of several genes. Second, the activity of mTORC1, an important integrator of metabolic signals, is inhibited by hypoxia. Third, hypoxia can trigger the UPR. In recent years, evidence from both laboratory and clinical studies has indicated that hypoxia is a strong activator of the UPR. XBP1, an essential survival factor, is necessary under hypoxic conditions [32]. XBP1 maintains the hypoxia response by regulating HIF1α transcription, thereby ensuring maximum HIF activity and an adaptive response to the cytotoxic microenvironment of tumors [9]. It has been suggested that RCN1 promotes cancer cell survival under hypoxia [33]. Additional research is required to explore the relationship between RCN1 expression and hypoxia.

There have been reports that RCN1 is aberrantly expressed in a variety of tumors. However, there are limited studies on the role of RCN1 in tumors, and the role of RCN1 in the development and treatment of liver cancer is still unknown. In the present study, we report for the first time the vital role of RCN1 and its downstream pathway in sorafenib resistance in HCC. It is known that RCN1 inhibits PERK-CHOP-mediated UPR signaling during ER stress to prevent TM-induced cell death [14, 21, 23]. Surprisingly, however, we found that in sorafenib-resistant cells, RCN1 activates the IRE1α–XBP1 pathway to constitutively activate the UPR and thereby reduces sorafenib-induced apoptosis. We speculate that this may be one reason for sorafenib resistance in Huh7 and HepG2 cells. In response to chronic stress, many cancer cells activate the UPR through the IRE1α–XBP1 pathway in order to survive. IRE1α has been implicated in tumor tolerance against hypoxia and angiogenesis, and XBP1s, a transcription factor previously shown to be associated with cancer, is also elevated in hypoxic cells, where it provides a survival advantage [34]. In prostate cancer cells, Bag5 overexpression inhibits ER stress-induced apoptosis in the UPR by suppressing PERK-eIF2-ATF4 activity while enhancing the IRE1α–XBP1 axis [35]. Tay et al. demonstrated that sustained IRE1 signaling in the UPR is an
Fig. 3  RCN1 contributes to selective activation of the unfolded protein response. A qRT-PCR and western blot analysis showing the mRNA and protein levels of IRE1, CHOP, GRP78, and XBP1s in sorafenib-resistant and sorafenib-sensitive Huh7 cells. B Western blot analysis showing protein levels of XBP1 and p-IRE1α in sorafenib-resistant Huh7 cells with or without RCN1 silencing. C Total mRNA levels of XBP1 in RCN1-knockdown drug-resistant cells. D, E Western blot analysis of RCN1, IRE1α, and XBP1 expression in sorafenib-resistant Huh7 cells with downregulated or overexpressed IRE1. Data are presented as the means ± SEM of three independent experiments; data for western blot have undergone quantitative analysis. ns not significantly different. *P < 0.05; **P < 0.01; ***P < 0.001, t-test.
The IRE1α–XBP1s pathway is crucial for drug resistance and HCC malignancy. A Representative flow cytometry analysis of Annexin V-PI staining in sorafenib-resistant Huh7 cells with or without RCN1 silencing, in the presence of 5 μM sorafenib. B Representative flow cytometry analysis of Annexin V-PI staining in sorafenib-resistant Huh7 cells in the presence of 5 μM sorafenib and different doses of MKC8866. C Cell proliferation in sorafenib-resistant Huh7 cells with IRE1α knockdown assessed using an EdU assay. D Transwell assays of cell migration and invasion in sorafenib-resistant Huh7 cells after IRE1α knockdown. E Cell proliferation in sorafenib-resistant Huh7 cells assessed using EdU assays after treatment with 0.3 μM MKC8866. F Transwell assays of cell migration and invasion in sorafenib-resistant Huh7 cells in the presence of 0.3 μM MKC8866. Data are presented as the means ± SEM of three independent experiments. ns not significantly different. **P < 0.01; ***P < 0.001; ****P < 0.0001, t-test.
Fig. 5  The RCN1 EFh1/2 domain binds with GRP78 and promotes the dissociation of GRP78 from IRE1. A Immunoblot analysis of the interaction between GRP78 and IRE1α using immunoprecipitates from sorafenib-resistant Huh7 cells with or without RCN1 silencing. B Immunoblot analysis of complex formation between endogenous RCN1 and GRP78 immunoprecipitated from sorafenib-resistant Huh7 cells. C Schematic representation of the whole-length and deletion RCN1 mutants. D Immunoblot analysis of complex formation between endogenous GRP78 and HA-tagged mutant RCN1. E Immunoblot analysis of IRE1α phosphorylation and XBP1s protein levels in sorafenib-resistant Huh7 cells transfected with whole-length and deletion RCN1 mutants. Data are presented as the means ± SEM of three independent experiments. ns not significantly different. **P < 0.01; ***P < 0.001; ****P < 0.0001, t-test.
Fig. 6  RCN1 activates c-MYC signaling in sorafenib-resistant cells. A Signaling pathways affected by RCN1, analyzed using GSEA based on TCGA data. B mRNA levels of MYC in RCN1-knockdown sorafenib-resistant cells. C Western blot analysis showing protein levels of RCN1 and c-MYC in sorafenib-resistant Huh7 cells with or without RCN1 repression. D Intensity of c-MYC immunohistochemical staining in xenograft tumor sections. E Knockdown efficiency of MYC analyzed using western blot. F Apoptosis of sorafenib-resistant Huh7 cells with MYC knockdown in the presence of 5 μM sorafenib analyzed using flow cytometry. G Cell proliferation in sorafenib-resistant Huh7 cells with MYC knockdown assessed using an EdU assay. H Transwell assays of cell migration and invasion in sorafenib-resistant Huh7 cells after MYC knockdown. Data are presented as the means ± SEM of three independent experiments; data for western blot have undergone quantitative analysis. ns not significantly different. **P < 0.01; ***P < 0.001; ****P < 0.0001, t-test.
important protective mechanism against ER stress-induced apoptosis in melanoma cells [36]. In particular, when HCC cells encounter ER stress due to in vitro sorafenib treatment, the activation of the IRE1α–XBP1 signaling pathway plays a protective role [8]. Our study proposes for the first time that RCN1 can activate the UPR under certain circumstances and promote tumor cell survival instead of inhibiting PERK-CHOP-mediated UPR signaling during ER stress.

In cancer, the genetic deregulation of MYC expression drives malignant transformation [37] and is implicated in
The activation of c-MYC can promote the resistance of liver cancer cells to sorafenib [13, 39]. Previous research has established a link between UPR and c-MYC, and it is known that the IRE1α–XBP1s pathway promotes prostate cancer development by activating c-MYC signaling. Here we demonstrate, for the first time, that the central oncogenic c-MYC signaling pathway, previously shown to have important roles in HCC, is directly activated by IRE1α signaling via XBP1s in sorafenib-resistant cells. Interestingly, we found that the total levels of XBP1 were also decreased in RCN1-knockdown sorafenib-resistant cells (Fig. 3C). Hong et al. [40] found that MYC activates the pro-survival IRE1α–XBP1 pathway in HCC. Additional studies are required to establish whether c-MYC regulates IRE1α expression and XBP1 activity in sorafenib-resistant cells. If so, this would imply that the XBP1s-c-MYC axis enables a powerful feedback loop to establish a survival pathway in sorafenib-resistant cells.

In this study, we demonstrated that RCN1 is overexpressed in sorafenib-resistant cells and activates the IRE1α–XBP1s–c-MYC pathway. Moreover, RCN1 is upregulated in the presence of lenvatinib, regorafenib, and certain cytokines. Our results reveal the role of the IRE1α–XBP1s–c-MYC axis in sorafenib-resistant HCC cells and the molecular mechanisms of its action. These findings suggest that targeting RCN1 may help in preventing sorafenib resistance in HCC and inhibit tumor progression. In the future, we will explore the role of RCN1 in the HIF1α signaling pathway and evaluate whether c-MYC regulates IRE1α expression and XBP1 activity in sorafenib-resistant cells. Additional studies will also be necessary to investigate the role of RCN1 in tumor stromal cells.

MATERIALS AND METHODS
Cell culture
The human HCC cell lines (MHCC-LM3, MHCC-97H, Hep3B, HepG2, and Huh7) were procured from the Shanghai Institutes for Biological Sciences (China) Cell Center. In order to establish sorafenib resistance in vitro, these cells were exposed to 1.5 μM sorafenib at first, and this concentration was gradually increased to 6 μM via weekly increases for 8 months. All cell lines were incubated in humidified air containing 5% CO₂ at 37°C and cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% fetal bovine serum (FBS), 100 IU/mL penicillin, and 100 μg/mL streptomycin.
**Immunohistochemistry**

For immunohistochemistry (IHC), we prepared formalin-fixed paraffin-embedded primary HCC tissue sections and resected xenografts according to the manufacturer’s protocol (Servicebio, GP1001, GP1010) and incubated them with the corresponding primary antibodies at 37°C for 2 h. Following this, they were incubated with goat anti-rabbit antibody against immunoglobulin G (Servicebio, G1213). The primary IHC antibodies were as follows: anti-RCN1 (Abcam, ab210404), anti-PCNA (Servicebio, GB11010), and anti-c-MYC (Proteintech, 10828-1-AP).

**Animal experiments**

All experimental protocols and animal care methods were approved by the guidelines of the Nanjing Medical University (NJMU) Institutional Animal Care and Use Committee. In order to evaluate the tumor-development capacity of the sorafenib-resistant cells, ~1 × 10^5 cells with or without RCN1 knockdown were suspended in 100 μl phosphate-buffered saline (PBS) and then transplanted subcutaneously into the flank of 4–6-week-old male NOD/SCID mice (Vital River, Beijing, China) (randomly divided into different groups, with 10 mice per control group and 10 mice per experimental group). The mice were maintained under specific pathogen-free conditions. Tumor development was monitored regularly. Tumor volume was calculated using the following formula: V = (L x W^2) / 2 (V, volume; L, length diameter; W, width diameter). When the tumors reached 5 mm × 5 mm (L x W) in size, the mice were randomized for treatment with sorafenib (25 mg/kg/day, orally) or vehicle (DMSO). After 3–4 weeks, mice were killed, and the tumors were dissected.

**Vector construction**

For the knockdown of gene expression, short-hairpin RNAs (shRNAs) were designed and cloned into the lentiviral vector pLKO.1-puro. The empty vector was used as a negative control. Puromycin (2 μg/mL) (Thermo Fisher Scientific, USA) was used to generate antibiotic-resistant cells for subsequent assays. The sequences of the shRNAs are shown in Supplementary Table S1. RCN1 EF-hand deletion mutants were constructed using pcDNA3.1-HA vectors. The cloning primers are shown in Supplementary Table S2. IRE1, MYC, and XBP1s cDNA was also inserted into pcDNA3.1 or pcDNA3.1-Flag vectors, and the empty vector was used as a negative control.

**RNA extraction and quantitative real-time PCR**

RNA was extracted from harvested cells using the TRBzol reagent (Invitrogen, USA). The total RNA (1 μg) was reverse transcribed into cDNA according to the manufacturer’s instructions (Vazyme, R323-01). An equivalent volume of cDNA per sample was prepared for real-time PCR analysis using SYBR Green (Vazyme, Q711-02). qRT-PCR data were analyzed using the relative gene expression method and normalized based on GAPDH levels. The primer sequences used for qRT-PCR are shown in Supplementary Table S3.

**Statistical analysis**

All data were analyzed using GraphPad Prism 8.0 software (La Jolla, CA, USA) and SPSS 24.0. All testing was done blind, in duplicate by two technicians. Statistical significance was determined by a two-tailed unpaired t-tests (2 groups), or one-way ANOVA (>2 groups) with Bonferroni’s multiple comparisons test. All in vitro functional assays are representations of at least three independent experiments expressed as mean ± SD. P-values < 0.05 were considered statistically significant.

Additional experimental procedures are provided in the Supplementary Information.

**DATA AVAILABILITY**

The datasets generated and/or analyzed during the current study are available from the corresponding authors on reasonable request.

**REFERENCES**

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

2. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009;69:223–40.

3. Yang JD, Hainaut P, Gores GJ, Amardou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Rev Gastroenterol Hepatol. 2019;16:589–604.

4. Cheng A-L, Yang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:325–34.

5. Shen H, Liao R, Wang J, et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 2011;7:1159–72.

6. Senft D, Ronai ZA. UPR, autophagy, and mitochondria cross-talk underlies the ER stress response. Trends Biochem Sci. 2015;40:141–8.

7. Wang M, Kaufman RJ. The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer. 2014;14:581–97.

8. Zhou T, Lv X, Guo X, Ruan B, Liu D, Ding R, et al. RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis. Oncol Rep. 2015;33:3006–14.

9. Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatzistoloulo M, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature 2014;508:103–7.

10. Cuevas EP, Eraso P, Mazon MJ, Santos V, Moreno-Bueno G, Cano A, et al. LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway. Sci Rep. 2017;7:44988.

11. Sheng X, Nenseth HZ, Qu S, Kuzu OF, Frahnow T, Simon L, et al. IRE1alpha-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nat Commun. 2019;10:323.

12. Shachaf CM, Kopelman AM, Arvantitis C, Karlsson A, Beer S, Mandll S, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112–7.

13. Liu R, Li Y, Tian L, Shi H, Wang J, Liang Y, et al. Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating beta-catenin/c-Myc signaling in human hepatocellular carcinoma. Cancer Lett. 2019;443:34–46.

14. Liu X, Zhang N, Wang D, Zhu D, Yuan Q, Zhang X, et al. Downregulation of reticulocalbin-1 differentially facilitates apoptosis and necroptosis in human prostate cancer cells. Cancer Sci. 2018;109:1147–57.

15. Zhang JZ, Wu ZH, Cheng Q. Screening and identification of key biomarkers in nasopharyngeal carcinoma: evidence from bioinformatic analysis. Medicine. 2019;98:e17997.

16. YU LR, Zeng R, Shao XX, Wang N, Xu YH, Xia QC. Identification of differentially expressed proteins between human hepatoma and normal liver cell lines by two-dimensional electrophoresis and liquid chromatography-ion trap mass spectrometry. Electrophoresis 2000;21:3058–68.

17. Chen X, Shao W, Huang H, Feng X, Yao S, Ke H. Overexpression of RCN1 correlates with poor prognosis and progression in non-small cell lung cancer. Hum Pathol. 2019;43:180–4.

18. Liu Z, Brattain MG, Appert H. Differential display of reticulocalbin in the highly invasive cell line, MDA-MB-435, versus the poorly invasive cell line, MCF-7. Biochem Biophys Res Commun. 1997;231:283–9.

19. Nimmrich I, Erdmann S, Melchers U, Hinke U, Hentsch S, Simon L, et al. Seven genes that are differentially transcribed in colorectal tumor cell lines. Cancer Lett. 2000;160:37–43.

20. Watanabe M, Takemasa I, Kawaguchi N, Miyake N, Nishimura M, Matsubara T, et al. An application of the 2-nitrobenzenesulfonyl method to proteomic profiling of human colorectal carcinoma: a novel approach for biomarker discovery. Proteom Clin Appl. 2008;2:925–35.

21. Huang ZH, Qiao J, Feng Y, Liu MT, Cheng T, Wang J, et al. Reticulocalbin-1 knockdown increases the sensitivity of cells to Adriamycin in nasopharyngeal carcinoma and promotes endoplasmic reticulum stress-induced cell apoptosis. Cell Cycle. 2020;19:1576–89.

22. May EW, Lin ST, Lin CC, Chang JF, Hung E, Lo YW, et al. Identification of up- and down-regulated proteins in doxorubicin-resistant canine uterine cancer cells: reticulocalbin-1 plays a key role in the development of doxorubicin-associated resistance. Pharmacol Res. 2014;90:1–17.

23. Xu S, Xu Y, Chen L, Fang Q, Song S, Chen J, et al. RCN1 suppresses ER stress-induced apoptosis via calcium homeostasis and PERK-CHOP signaling. Oncogenesis 2017;6:e304.

24. Li X, Zhang X. Unfolded protein response in cancer: the physician’s perspective. J Hematol Oncol. 2011;4:8.

25. Cubillos-Ruiz JR, Bettigole SE, Glimerch LH. Tumorigenic and immunosuppressive effects of endoplasmic reticulum stress in cancer. Cell. 2017;168:692–706.

26. Song M, He J, Pan GZ, Yang J, Zhao J, Zhang YJ, et al. Cancer-associated fibroblast-mediated cellular crossstalk supports hepatocellular carcinoma progression. Hepatology 2021;73:1717–35.
ACKNOWLEDGEMENTS

The authors thank Shen-Ping Zhou, Xue-Hui Long, and Bei Zhang from Nanjing Medical University. This work was supported by grants from the National Natural Science Foundation of China (81971495, 81571564, and 91442117), the CAMS Innovation Fund for Medical Sciences (No. 2019-I2M-5-035), the National Science Foundation of Jiangsu Province (BRA2017533, BK20191490, and BE2016766), the 863 Young Scientists Special Fund (SS2015AA0209322), and the Foundation of Jiangsu Collaborative Innovation Center of Biomedical Functional Materials.